Retrogenix advances medical research and speeds up drug discovery for its clients by providing a unique service which identifies specific cell surface and secreted protein interactions in human cells. Our results help scientific breakthroughs to be made; assist with critical decision making in pharmaceutical development; and provide key data to support the regulatory applications that are required before new medicines can be safely given to patients. Retrogenix now has research agreements with all top twenty global pharmaceutical companies, numerous drug discovery companies and many leading academic and non-for-profit institutions around the world.
Our results have been published in many high-impact journals including: Nature, Nature Medicine, JBC, Molecular Cancer, Cancer Cell, Cancer Immunology Research, J. Med. Chem., mAbs, mBio and Oncotarget. Members of our team are regularly invited to present at international conferences. In 2015, Retrogenix won its first Queen’s Award for Enterprise – the UK’s most prestigious business accolade – in recognition of its innovative work in developing and commercialising the cell microarray technology. This was followed in 2017 by a second Queen’s Award for outstanding achievements in international trade.
As well as the unique cell microarray technology, Retrogenix also holds one of the world’s largest collections of plasma membrane and secreted protein clones which are individually expressed in human cells. The collection now exceeds 6,200 full-length expression clones, with many proteins represented by multiple variants.
Part of the Charles River Group, Retrogenix is based in High Peak, UK, and all project work is undertaken by highly skilled scientists in our specialist laboratory facilities on-site.